Antisense Therapeutics: Receives first approval for phase two DMD clinical trial

Antisense Therapeutics Receives first approval for phase two DMD clinical trial

• Antisense Therapeutics (ANP) receives approval to conduct its phase two trial in non-ambulant boys with Duchenne muscular dystrophy (DMD) in Turkey
• The approval came from the Turkish Medicines and Medical Device Agency to conduct a double-blind, placebo-controlled trial of ATL1102
• This marks the company’s first trial approval by a regulatory authority
• The company expects further trial approvals in Bulgaria, the UK and Australia, depending on each regulatory agencies’ evaluation process and timelines
• AntisenseTherapeutics last traded at 9.6 cents on February 13